---
title: "REPL Stock Rockets 85.68% After Promising Cancer Therapy Data at ASCO"
canonical_url: https://www.stockexpertai.com/journal/2026-05-30/repl-stock-rockets-8568-after-promising-cancer-therapy-data-at-asco-2
last_updated: 2026-05-30T18:18:36.914Z
section: "Stock of the Day"
author: "Sam Rivera"
publisher: Stock Expert AI
tickers: REPL, MGPI, MORN, GRAL, COGT, MU
content_type: journal-article
---

# REPL Stock Rockets 85.68% After Promising Cancer Therapy Data at ASCO

## The Take
- REPL's surge highlights the potential of oncolytic immunotherapies; monitor clinical trial progress and regulatory milestones closely.

_Replimune shares surge on positive clinical trial results for its oncolytic immunotherapy, RP1, presented at the ASCO annual meeting._

Replimune Group, Inc. (REPL) is in the spotlight today after its stock price jumped 85.68%. This name deserves a closer look as the surge is directly linked to the presentation of 3-year overall survival data from its IGNYTE clinical trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The IGNYTE trial evaluated RP1, Replimune's oncolytic immunotherapy, in combination with nivolumab, for patients with melanoma who had previously failed anti-PD-1 therapy. The data appears promising, offering a potential treatment avenue for a challenging patient population. Oncolytic immunotherapies represent a cutting-edge area of cancer treatment, and Replimune is positioning itself as a key player in this space. The presentation at ASCO, a major event in the oncology community, has clearly captured investor attention.

Beyond the clinical trial data, Replimune's focus on novel oncolytic immunotherapies aligns with the growing demand for innovative cancer treatments. As a clinical-stage biotechnology company, Replimune operates in a high-growth market, but also carries the inherent risks associated with drug development. Investors should carefully consider the company's pipeline, financial position, and the regulatory landscape.

Key Metrics:
* Ticker: REPL
* Price: $8.69
* Change: +85.68%

## Related Tickers
- [REPL](https://www.stockexpertai.com/stock/repl)
- [MGPI](https://www.stockexpertai.com/stock/mgpi)
- [MORN](https://www.stockexpertai.com/stock/morn)
- [GRAL](https://www.stockexpertai.com/stock/gral)
- [COGT](https://www.stockexpertai.com/stock/cogt)
- [MU](https://www.stockexpertai.com/stock/mu)

## Frequently Asked Questions

### What is Replimune (REPL)?
Replimune Group, Inc. (REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment. Their lead product, RP1, is being evaluated in clinical trials, including the IGNYTE trial discussed in this article. The company's stock price has recently seen significant movement due to positive data releases.

### Why did REPL stock price increase?
REPL stock surged due to promising 3-year overall survival data from the IGNYTE clinical trial of its RP1 immunotherapy presented at the ASCO annual meeting. This data suggests potential efficacy in treating melanoma patients who have not responded to previous therapies, leading to increased investor interest.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._